The Institute for Quality and Efficiency in Health Care (IQWiG) was commissioned by the Federal Joint Committee (G-BA) to ...

Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 (received in ...

Moderna stock crashed Thursday after the Covid vaccine maker slashed its R&D budget and issued a light sales view.

In an effort to build its commercial capacity, Moderna on Thursday announced it is lowering research and development spending ...

Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination vaccine for approval in 2024Announces positive ...

DBS analyst Mark Kong CFA has maintained their bullish stance on MRNA stock, giving a Buy rating yesterday. Mark Kong CFA has given his Buy ...

Moderna plans to cut $1.1bn in costs by 2027, pausing and scrapping several R&D programs. See why I think further downside ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination vaccine for approval in 2024Announces positive ...

Milan, Italy, 12 September 2024 – Genespire, a biotechnology company developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases, today announces the appointment of ...

Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 (received in August 2024) upon first sale of Ipsen's Iqirvo® (elafibran ...